dodecyl prop-2-enoate | CAS:2156-97-0

We serve dodecyl prop-2-enoate CAS:2156-97-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
dodecyl prop-2-enoate

Chemical Name:dodecyl prop-2-enoate
CAS.NO:2156-97-0
Synonyms:dodecyl prop-2-enoate
Dodecyl Acrylate
Acrylic acid,dodecyl ester
n-Dodecyl acrylate
Molecular Formula:C15H28O2
Molecular Weight:240.38200
 
Physical and Chemical Properties:
Density:0.884
Melting point:4ºC
Boiling point:120ºC
Flash point:>230°F
Index of Refraction:1.445
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like dodecyl prop-2-enoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-Dodecyl acrylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Dodecyl Acrylate Use and application,Acrylic acid,dodecyl ester technical grade,usp/ep/jp grade.


Related News: High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.2-(7-Azabenzotriazole-1-yl)-1,1,3,3-Tetramethyluronium Tetrafluoroborate manufacturer The best you can do is take medicines and treatments for specific symptoms.12-bromododec-1-ene supplier The term active pharmaceutical ingredient may refer to an active chemical within an FDA-regulated drug, or API might mean the entire drug with its active and inactive ingredients.5-Bromopyrimidine vendor With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. nearPatents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.